At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 858 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil
In Brief
A Phase 3 clinical trial evaluating Placebo and Idalopirdine for Alzheimer's Disease. Completed, enrolled 858 participants across 162 sites in 19 countries.
Detailed Summary
To establish efficacy of Idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesArgentina, Brazil, Canada, Croatia, Czechia, Estonia, Finland, France, Hungary, Ireland, Israel, Italy, Lithuania, Poland, Portugal, South Korea, Taiwan, United Kingdom, United States
CollaboratorsOtsuka Pharmaceutical Co., Ltd.
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartFeb 2014
Primary CompletionDec 2016
TodayJul 2026
First PostedDec 10, 2013
Enrollment StartFeb 1, 2014
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.6 years ago
Interventions
Placebodrug
Once daily, matching placebo capsules, orally
Idalopirdinedrug
Once daily, encapsulated tablets, orally